Jadcherala Telangana News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Shilpa Medicare fell 1.25% to Rs 424.30, extending losses for third day.
The stock has declined 1.6% in three sessions from its recent closing high of Rs 431 on 10 February 2021.
In the past six months, the stock has declined by 31.99% while the benchmark Sensex has added 37.61% during the same period.
In a BSE filing made during market hours today, Shilpa Medicare announced the launch of Sunitinib capsules, under the brand name SUNISHIL in India. The Sunitinib capsules has been launched in three strengths of 12.5 mg, 25 mg and 50 mg
Sunitinib malate is a novel oral multi targeted tyrosine kinase inhibitor with antitumor and antiangiogenic activities. The drug is indicated for the treatment of G.I. Stromal tumor after disease progression on or intolerance to Imatinib mesylate, advanced Renal Cell Carcinoma, and for the treatment of Unresectable or Metastatic Welldifferentiated Pancreatic Neuroendocrine Tumors with Disease Progression in adults. ....

Jadcherala Telangana , Shilpa Medicare , Renal Cell Carcinoma , Disease Progression , Sunitinib Capsules , Capital Market , S Ampp Bse Sensex Index , Metastatic Welldifferentiated Pancreatic Neuroendocrine Tumors , Skullcandygi Headphone Headset , Gi Stromal Tumor , ஷில்பா மருத்துவ , சிறுநீரகம் செல் புற்றுநோய் , நோய் ப்ரோக்ரெஶந் , மூலதனம் சந்தை ,